» Articles » PMID: 32201620

The Global and Regional Burden of Genital Ulcer Disease Due to Herpes Simplex Virus: a Natural History Modelling Study

Overview
Journal BMJ Glob Health
Specialty Public Health
Date 2020 Mar 24
PMID 32201620
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Herpes simplex virus (HSV) infection can cause painful, recurrent genital ulcer disease (GUD), which can have a substantial impact on sexual and reproductive health. HSV-related GUD is most often due to HSV type 2 (HSV-2), but may also be due to genital HSV type 1 (HSV-1), which has less frequent recurrent episodes than HSV-2. The global burden of GUD has never been quantified. Here we present the first global and regional estimates of GUD due to HSV-1 and HSV-2 among women and men aged 15-49 years old.

Methods: We developed a natural history model reflecting the clinical course of GUD following HSV-2 and genital HSV-1 infection, informed by a literature search for data on model parameters. We considered both diagnosed and undiagnosed symptomatic infection. This model was then applied to existing infection estimates and population sizes for 2016. A sensitivity analysis was carried out varying the assumptions made.

Results: We estimated that 187 million people aged 15-49 years had at least one episode of HSV-related GUD globally in 2016: 5.0% of the world's population. Of these, 178 million (95% of those with HSV-related GUD) had HSV-2 compared with 9 million (5%) with HSV-1. GUD burden was highest in Africa, and approximately double in women compared with men. Altogether there were an estimated 8 billion person-days spent with HSV-related GUD globally in 2016, with 99% of days due to HSV-2. Taking into account parameter uncertainty, the percentage with at least one episode of HSV-related GUD ranged from 3.2% to 7.9% (120-296 million). However, the estimates were sensitive to the model assumptions.

Conclusion: Our study represents a first attempt to quantify the global burden of HSV-related GUD, which is large. New interventions such as HSV vaccines, antivirals or microbicides have the potential to improve the quality of life of millions of people worldwide.

Citing Articles

Estimated global and regional economic burden of genital herpes simplex virus infection among 15-49 year-olds in 2016.

Chaiyakunapruk N, Lee S, Kulchaitanaroaj P, Rayanakorn A, Lee H, Looker K BMC Glob Public Health. 2024; 2(1):42.

PMID: 39681948 PMC: 11618196. DOI: 10.1186/s44263-024-00053-6.


Breaching the Barrier: Investigating Initial Herpes Simplex Viral Infection and Spread in Human Skin and Mucosa.

Rana H, Truong N, Sirimanne D, Cunningham A Viruses. 2024; 16(11).

PMID: 39599904 PMC: 11599041. DOI: 10.3390/v16111790.


Global, Regional, and National Trends Analysis in Incidence of Genital Herpes Among the Population Aged 15-49 Years - Worldwide, 1990-2021.

Cao G, Liu J, Liu M, Liang W China CDC Wkly. 2024; 6(40):1033-1037.

PMID: 39502118 PMC: 11532514. DOI: 10.46234/ccdcw2024.214.


Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy.

Dahl D, Srinivasan P, Janusziewicz R, King J, Shrivastava R, Zhang J J Control Release. 2024; 376:1209-1224.

PMID: 39500407 PMC: 11866343. DOI: 10.1016/j.jconrel.2024.10.059.


Population-based risk factors and urogenital comorbidities associated with genital herpes: A nationwide study of 4 million women.

Sundqvist C, Li X, Borgfeldt C, Forsberg P, Sundquist K, Jansaker F IJID Reg. 2024; 13:100457.

PMID: 39435377 PMC: 11491714. DOI: 10.1016/j.ijregi.2024.100457.


References
1.
Peacock Jr J, Kaplowitz L, Sparling P, Durack D, Gnann Jr J, Whitley R . Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med. 1988; 85(3):301-6. DOI: 10.1016/0002-9343(88)90578-5. View

2.
Brown Z, Selke S, Zeh J, Kopelman J, Maslow A, Ashley R . The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997; 337(8):509-15. DOI: 10.1056/NEJM199708213370801. View

3.
Kinghorn G, Abeywickreme I, Jeavons M, Rowland M, Barton I, POTTER C . Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes. Genitourin Med. 1986; 62(1):33-7. PMC: 1011886. DOI: 10.1136/sti.62.1.33. View

4.
REEVES W, Corey L, ADAMS H, Vontver L, Holmes K . Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med. 1981; 305(6):315-9. DOI: 10.1056/NEJM198108063050604. View

5.
Fife K, Warren T, Justus S, Heitman C . An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sex Transm Dis. 2008; 35(7):668-73. DOI: 10.1097/OLQ.0b013e31816d1f42. View